NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $128.70 -1.40 (-1.08 %) (As of 02/17/2020 04:00 PM ET) Add Compare Today's Range$127.41Now: $128.70▼$130.8350-Day Range$114.65MA: $119.83▼$133.9952-Week Range$65.81Now: $128.70▼$134.51Volume398,981 shsAverage Volume696,423 shsMarket Capitalization$14.49 billionP/E RatioN/ADividend YieldN/ABeta2.47 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALNY Previous Symbol CUSIP02043Q10 CIK1178670 Webhttp://www.alnylam.com/ Phone617-551-8200Debt Debt-to-Equity Ratio0.19 Current Ratio4.87 Quick Ratio4.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$219.75 million Price / Sales65.93 Cash FlowN/A Price / Cash FlowN/A Book Value$12.90 per share Price / Book9.98Profitability EPS (Most Recent Fiscal Year)($8.11) Net Income$-886,120,000.00 Net Margins-403.24% Return on Equity-55.82% Return on Assets-36.67%Miscellaneous Employees1,065 Outstanding Shares112,580,000Market Cap$14.49 billion Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive ALNY News and Ratings via Email Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALNY Rates by TradingView Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions What is Alnylam Pharmaceuticals' stock symbol? Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY." How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its earnings results on Thursday, February, 6th. The biopharmaceutical company reported ($2.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.25) by $0.22. The biopharmaceutical company had revenue of $71.70 million for the quarter, compared to analyst estimates of $71.45 million. Alnylam Pharmaceuticals had a negative return on equity of 55.82% and a negative net margin of 403.24%. The firm's revenue for the quarter was up 241.4% on a year-over-year basis. During the same period last year, the company posted ($1.82) earnings per share. View Alnylam Pharmaceuticals' Earnings History. When is Alnylam Pharmaceuticals' next earnings date? Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals. What price target have analysts set for ALNY? 17 brokers have issued 12 month price objectives for Alnylam Pharmaceuticals' shares. Their forecasts range from $70.00 to $190.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $125.71 in the next year. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Alnylam Pharmaceuticals. What is the consensus analysts' recommendation for Alnylam Pharmaceuticals? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals. What are Wall Street analysts saying about Alnylam Pharmaceuticals stock? Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock: 1. According to Zacks Investment Research, "Alnylam incurred narrower-than-expected loss and beat revenue estimates in the third quarter of 2019. Onpattro continued to gain traction. The FDA set an action date of Feb 20, 2020. It showed strong commitment toward future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro for patients with cardiomyopathy and a potential label expansion should boost sales.The company’s efforts to develop its pipeline (inclisiran and lumasiran) are impressive. The company also expects to submit an NDA for inclisiran in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, heavy dependence on Onpattro for growth is a concern. Moreover, the company heavily relies on its partnerships for supporting operations.Shares have outperformed the industry." (11/19/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019) Has Alnylam Pharmaceuticals been receiving favorable news coverage? News articles about ALNY stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Alnylam Pharmaceuticals. Are investors shorting Alnylam Pharmaceuticals? Alnylam Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,800,000 shares, an increase of 8.6% from the January 15th total of 4,420,000 shares. Based on an average daily trading volume, of 723,500 shares, the days-to-cover ratio is currently 6.6 days. Approximately 4.4% of the company's stock are sold short. View Alnylam Pharmaceuticals' Current Options Chain. Who are some of Alnylam Pharmaceuticals' key competitors? Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU). Who are Alnylam Pharmaceuticals' key executives? Alnylam Pharmaceuticals' management team includes the folowing people: Dr. John M. Maraganore, CEO & Exec. Director (Age 56)Mr. Barry E. Greene, Pres (Age 56)Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56) Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Baillie Gifford & Co. (7.34%), State Street Corp (2.60%), Maverick Capital Ltd. (2.03%), Farallon Capital Management LLC (1.30%) and UBS Asset Management Americas Inc. (0.74%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Paul Schimmel, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals. Which major investors are selling Alnylam Pharmaceuticals stock? ALNY stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Fred Alger Management LLC, First Trust Advisors LP, State Street Corp, Sectoral Asset Management Inc, Casdin Capital LLC, Pictet Asset Management Ltd. and Franklin Resources Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals. Which major investors are buying Alnylam Pharmaceuticals stock? ALNY stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bridger Management LLC, Cubist Systematic Strategies LLC, California Public Employees Retirement System, Great West Life Assurance Co. Can, DCF Advisers LLC, FMR LLC and Parkman Healthcare Partners LLC. View Insider Buying and Selling for Alnylam Pharmaceuticals. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Alnylam Pharmaceuticals' stock price today? One share of ALNY stock can currently be purchased for approximately $128.70. How big of a company is Alnylam Pharmaceuticals? Alnylam Pharmaceuticals has a market capitalization of $14.49 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals. What is Alnylam Pharmaceuticals' official website? The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/. How can I contact Alnylam Pharmaceuticals? Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected] MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 956 (Vote Outperform)Underperform Votes: 476 (Vote Underperform)Total Votes: 1,432MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: Why are percentage gainers important?
